Penumbra, Inc. Reports First Quarter 2025 Financial Results

, /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024. U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024. Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025. Net income of $39.2 million and adjusted EBITDA1 of $59.6 million or net income margin of 12.1% and adjusted EBITDA margin1 of 18.4% in the first quarter of 2025. First Quarter 2025 Financial ResultsTotal revenue increased to $324.1 million for the first quarter of 2025 compared to $278.7 million for the first quarter of 2024, an increase of 16.3%, or 16.9% in constant currency1. The United States represented 79.2% of total revenue and international represented 20.8% of total revenue for the first quarter of 2025. Revenue from the U.S. increased 22.5% while revenue from our international regions decreased 2.5%, or 0.1% in constant currency1. Revenue from sales of our global thrombectomy products grew to $226.5 million in the first quarter of 2025, an increase of 20.7%, or 21.2% in constant currency1 over the same period a year ago, driven primarily by the sales of our U.S. thrombectomy products which increased by 25.0% over the same period a year ago. Revenue from sales of our global embolization and access products grew to $97.6 million for the first quarter of 2025, an increase of 7.3%, or 8.1% in constant currency1 from the same period a year ago, driven primarily by our U.S. embolization and access products which increased by 16.2% from the same period a year ago. Gross profit for the first quarter of 2025 was $215.9 million, or 66.6% of total revenue compared to $181.1 million, or 65.0% of total revenue, for the first quarter of 2024. The improvement in gross margin was primarily driven by favorable product mix across our regions and productivity improvements. Gross margin is impacted by product mix, regional mix, and production initiatives to support demand and create future efficiencies. As such, with favorable product mix, improvement in productivity, and by leveraging our fixed costs on higher volume of new product sales during the year, our gross margin may be positively impacted in the future. Total operating expenses and non-GAAP operating expenses were $175.5 million, or 54.2% of total revenue for the first quarter of 2025. This compares to total operating expenses of $169.0 million, or 60.7% of total revenue for the first quarter of 2024, which included $4.8 million in non-recurring litigation related expenses and a $2.4 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition. Excluding the charges noted above, total non-GAAP operating expenses1 were $161.8 million, or 58.1% of total revenue for the first quarter of 2024. R&D expenses were $22.1 million for the first quarter of 2025, compared to $24.6 million for the first quarter of 2024. SG&A expenses were $153.5 million for the first quarter of 2025, compared to $144.4 million for the first quarter of 2024. Income from operations and non-GAAP income from operations was $40.4 million for the first quarter of 2025, compared to income from operations of $12.1 million for the first quarter of 2024. Excluding $4.8 million in non-recurring litigation related expenses and a $2.4 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, non-GAAP income from operations1 was $19.3 million for the first quarter of 2024. 1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. Full Year 2025 Financial OutlookThe Company reiterates guidance for total revenue for 2025 to be in the range of $1,340 million to $1,360 million. The Company is increasing guidance for the U.S. Thrombectomy franchise growth to 20% to 21% year over year from 19% to 20% previously. The Company reiterates guidance for gross margin expansion of at least 100 basis points in 2025, to more than 67% for the full year, and operating margin expansion to a range of 13% to 14% of revenue for full year 2025. Webcast and Conference Call InformationPenumbra, Inc. will host a conference call to discuss the first quarter 2025 financial results after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at: www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call. About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X. Non-GAAP Financial MeasuresIn addition to financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses the following non-GAAP financial measures in this press release: a) constant currency, b) non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted earnings per share ("EPS") and c) adjusted EBITDA and adjusted EBITDA margin. Constant Currency. The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company's results or business. Non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of: the effect of the amortization of finite lived intangible assets acquired in connection with the Sixense acquisition over their estimated useful lives; the excess tax benefits associated with share-based compensation arrangements; and non-recurring litigation related expenses. Adjusted EBITDA and adjusted EBITDA margin. The Company's adjusted EBITDA reflects the exclusion from GAAP net income of: non-cash operating charges such as stock-based compensation and depreciation and amortization; non-operating items such as interest income, interest expense, and provision for (benefit from) income taxes; and non-recurring litigation related expenses. Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below. Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, the excess tax benefits associated with share-based compensation arrangements, and expenses related to certain litigation matters that we have determined are not a normal or recurring part of our business, including settlement costs and legal fees. Further, we consider adjusted EBITDA and adjusted EBITDA margin useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding non-cash operating charges such as stock-based compensation and depreciation and amortization, non-operating items such as interest income, interest expense, and provision for (benefit from) income taxes and non-recurring litigation related expenses. The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. Forward-Looking StatementsExcept for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 18, 2025. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. Penumbra, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands) March 31, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 376,054 $ 324,404 Marketable investments 2,794 15,727 Accounts receivable, net 167,981 167,668 Inventories 415,863 406,737 Prepaid expenses and other current assets 37,017 36,589 Total current assets 999,709 951,125 Property and equipment, net 72,465 62,641 Operating lease right-of-use assets 175,331 177,787 Finance lease right-of-use assets 27,126 28,018 Intangible assets, net 6,469 6,513 Goodwill 166,123 165,826 Deferred taxes 102,355 100,332 Other non-current assets 43,729 40,939 Total assets $ 1,593,307 $ 1,533,181 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 31,153 $ 31,326 Accrued liabilities 112,675 112,429 Current operating lease liabilities 12,510 12,221 Current finance lease liabilities 2,292 2,369 Total current liabilities 158,630 158,345 Non-current operating lease liabilities 184,652 187,068 Non-current finance lease liabilities 21,201 21,731 Other non-current liabilities 15,942 15,106 Total liabilities 380,425 382,250 Stockholders' equity: Common stock 39 38 Additional paid-in capital 1,116,746 1,096,732 Accumulated other comprehensive loss (3,130) (5,843) Retained earnings 99,227 60,004 Total stockholders' equity 1,212,882 1,150,931 Total liabilities and stockholders' equity $ 1,593,307 $ 1,533,181 Penumbra, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts) Three Months Ended March 31, 2025 2024 Revenue $ 324,140 $ 278,655 Cost of revenue 108,257 97,516 Gross profit 215,883 181,139 Operating expenses: Research and development 22,077 24,626 Sales, general and administrative 153,456 144,412 Total operating expenses 175,533 169,038 Income from operations 40,350 12,101 Interest and other income, net 3,508 2,525 Income before income taxes 43,858 14,626 Provision for income taxes 4,635 3,624 Net income $ 39,223 $ 11,002 Net income per share: Basic $ 1.02 $ 0.28 Diluted $ 1.00 $ 0.28 Weighted average shares outstanding: Basic 38,562,191 38,717,334 Diluted 39,163,428 39,387,359 Penumbra, Inc. Reconciliation of GAAP Operating Expenses and GAAP Income from Operations to Non-GAAP Operating Expenses and Non-GAAPIncome from Operations1 (unaudited) (in thousands) Three Months Ended March 31, 2025 2024 GAAP operating expenses $ 175,533 $ 169,038 GAAP operating expenses includes the effect of the following items: Non-recurring litigation related expenses — 4,823 Amortization of finite lived intangible assets acquired — 2,380 Non-GAAP operating expenses $ 175,533 $ 161,835 GAAP income from operations $ 40,350 $ 12,101 GAAP income from operations includes the effect of the following items: Non-recurring litigation related expenses — 4,823 Amortization of finite lived intangible assets acquired — 2,380 Non-GAAP income from operations $ 40,350 $ 19,304 _______________________ 1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. Penumbra, Inc. Reconciliation of GAAP Net Income and GAAP Diluted EPS to Non-GAAP Net Income and Non-GAAP Diluted EPS1 (unaudited) (in thousands, except share and per share amounts) Three Months Ended March 31, 2025 Three Months Ended March 31, 2024 Net income Diluted EPS Net income Diluted EPS GAAP net income $ 39,223 $ 1.00 $ 11,002 $ 0.28 GAAP net income includes the effect of the following items: Non-recurring litigation related expenses — — 4,823 0.12 Amortization of finite lived intangible assets acquired — — 2,380 0.06 Tax effects on the non-GAAP adjustments above2 — — (1,736) (0.04) Excess tax benefits related to stock compensation awards (6,593) (0.17) (287) (0.01) Non-GAAP net income $ 32,630 $ 0.83 $ 16,182 $ 0.41 GAAP diluted EPS $ 1.00 $ 0.28 Non-GAAP diluted EPS $ 0.83 $ 0.41 Weighted average shares outstanding used to compute: GAAP diluted EPS 39,163,428 39,387,359 Non-GAAP diluted EPS 39,163,428 39,387,359 _______________________ 1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. 2For the three months ended March 31, 2024, management used a combined federal and state tax rate of 24.10%, to compute the tax effect of non-GAAP adjustments. Penumbra, Inc. Reconciliation of GAAP Net Income and GAAP Net Income Margin to Adjusted EBITDA and Adjusted EBITDA Margin1 (unaudited) (in thousands, except for percentages) Three Months Ended March 31, 2025 2024 GAAP net income $ 39,223 $ 11,002 Adjustments to GAAP net income: Depreciation and amortization expense 5,015 7,519 Interest income, net (3,063) (2,891) Provision for income taxes 4,635 3,624 Stock-based compensation expense 13,785 13,569 Non-recurring litigation related expenses — 4,823 Adjusted EBITDA $ 59,595 $ 37,646 Revenue $ 324,140 $ 278,655 Adjusted EBITDA $ 59,595 $ 37,646 GAAP net income margin 12.1 % 3.9 % Adjusted EBITDA margin 18.4 % 13.5 % _______________________ 1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. Penumbra, Inc. Reconciliation of Revenue Growth by Geographic Regions to Constant Currency Revenue Growth1 (unaudited) (in thousands, except for percentages) Three Months Ended March 31, Reported Change FX Impact Constant Currency Change 2025 2024 $ % $ $ % United States $ 256,860 $ 209,644 $ 47,216 22.5 % $ — $ 47,216 22.5 % International 67,280 69,011 (1,731) (2.5) % 1,646 (85) (0.1) % Total $ 324,140 $ 278,655 $ 45,485 16.3 % $ 1,646 $ 47,131 16.9 % Penumbra, Inc. Reconciliation of Revenue Change by Product Categories to Constant Currency Revenue Growth1 (unaudited) (in thousands, except for percentages) Three Months Ended March 31, Reported Change FX Impact Constant Currency Change 2025 2024 $ % $ $ % Thrombectomy $ 226,544 $ 187,703 $ 38,841 20.7 % $ 916 $ 39,757 21.2 % Embolization and Access 97,596 90,952 6,644 7.3 % 730 7,374 8.1 % Total $ 324,140 $ 278,655 $ 45,485 16.3 % $ 1,646 $ 47,131 16.9 % Penumbra, Inc. Reconciliation of Revenue Change by Product Categories and Geographic Regions to Constant Currency Revenue Growth1 (unaudited) (in thousands, except for percentages) Three Months Ended March 31, Reported Change FX Impact Constant Currency Change 2025 2024 $ % $ $ % Thrombectomy United States $ 187,893 $ 150,284 $ 37,609 25.0 % $ — $ 37,609 25.0 % International 38,651 37,419 1,232 3.3 % 916 2,148 5.7 % Total Thrombectomy 226,544 187,703 38,841 20.7 % 916 39,757 21.2 % Embolization and Access United States 68,967 59,360 9,607 16.2 % — 9,607 16.2 % International 28,629 31,592 (2,963) (9.4) % 730 (2,233) (7.1) % Total Embolization and Access 97,596 90,952 6,644 7.3 % 730 7,374 8.1 % Total $ 324,140 $ 278,655 $ 45,485 16.3 % $ 1,646 $ 47,131 16.9 % _______________________ 1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. Investor RelationsPenumbra, Inc.[email protected] SOURCE Penumbra, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Penumbra, Inc. Reports First Quarter 2025 Financial Results

FAQ

Why Bullish?

How important is it?

Why Short Term?

Related Companies

Related News